Thermo Fisher Scientific Inc. has opened a new clinical and commercial ultra-cold facility in the EU, expanding its clinical trial network in Europe to help accelerate the development of advanced therapies. The new current good manufacturing practice (cGMP) facility in Bleiswijk, Netherlands provides pharma and biopharma customers tailored, end-to-end support throughout the clinical supply chain for high-value therapies, including cell and gene therapies, biologics, antibodies and vaccines. To meet increasing demand from cell and gene therapy clinical trials in Europe, this facility builds on the company's market leadership and global CDMO capabilities in bioservices and specialty logistics services, including biorepository solutions and critical material storage.

The facility enables customers to meet clinical trial requirements regardless of scale or phase by leveraging its highly skilled and talented local workforce to partner with new and emerging biotech and established pharmaceutical companies. The site, 30 minutes outside of Amsterdam, offers clinical and commercial packaging services for cell and gene therapy products from development to commercialization, as well as end to end biorepository storage solutions and associated supply chain services. Capabilities include 5,000-square-meters (54,000 square feet) of ambient to cryogenic storage, ancillaries, and cold chain packaging, labeling, distribution as well as clinical QP release services.

In support of Thermo Fisher's commitment to sustainability and its global goal of achieving net-zero emissions by 2050, the Bleiswijk site uses 15% solar power and operates completely gas-free, provides sustainable heating and cooling with eco-friendly electric heat pumps, and uses ultramodern heat recovery technology. Thermo Fisher is dedicated to delivering end-to-end solutions to advance inclusive, impactful clinical research. In addition to the new facility in the EU, Thermo Fisher also recently expanded biologics manufacturing capacity in St.

Louis, opened a new cell therapy manufacturing facility in San Francisco, and launched an Innovation Lab in Pennsylvania.